IBCC - Núcleo de Pesquisa e Ensino (Site 0601)

The trials here

What the trial at this site is about, from its registry record.

Conditions

• Triple-negative breast cancer

Running trials

• Recruiting

  Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

  NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source

  Contact: Study Coordinator

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Triple-negative breast cancer1 recruiting